Holy Akwar | Science Advisor, Veterinary & AMR
International Centre for Antimicrobial Resistance Solutions (ICARS)

Holy Akwar, Science Advisor, Veterinary & AMR, International Centre for Antimicrobial Resistance Solutions (ICARS)

Holy Akwar is a dedicated Science Advisor specializing in Veterinary Medicine and Antimicrobial Resistance (AMR) at the International Centre for Antimicrobial Resistance Solutions (ICARS). With a strong background in veterinary science and a passion for combating AMR, Holy plays a crucial role in advancing research, development, and strategic partnerships within the global vaccine industry and public health.

Holy's expertise lies in bridging the gap between veterinary science and public health, with a focus on developing innovative solutions to address the growing threat of AMR. With a deep understanding of the complexities surrounding infectious diseases and antimicrobial resistance, Holy is at the forefront of shaping strategies to combat these challenges effectively.

Throughout Holy's career, he has demonstrated a commitment to driving positive change in the field of veterinary science and public health. By collaborating with key stakeholders, conducting cutting-edge research, and leveraging strategic partnerships, Holy is dedicated to advancing the development and implementation of vaccines to protect both animal and human populations.

As a speaker at the World Vaccine Congress Europe 2026, Holy Akwar brings a wealth of knowledge and experience to the discussion on research, development, and strategic partnering for the global vaccine industry. His insights and expertise are invaluable in shaping the future of vaccine development and combating antimicrobial resistance on a global scale.

Appearances:



Day 2 (21st October) @ 14:30

Panel: Bridging Species: Veterinary Vaccine Innovation for a Shared Health Future

  • How can platform technologies such as mRNA and viral vectors be adapted and approved efficiently across species? 
  • How can modern vaccine platforms (e.g., mRNA, viral vectors) be adapted and scaled for livestock and wildlife, and approved efficiently across species? How can human vaccine sites be used to manufacture animal vaccines? 
  • How do we incentivise R&D for high-impact livestock and wildlife diseases with limited commercial return? 
  • What models ensure equitable access to veterinary vaccines, particularly in LMICs? 
  • How can veterinary vaccination reduce antimicrobial use and support AMR strategies? 
last published: 04/Jun/26 10:05 GMT

back to speakers

Get involved at World Vaccine Congress Europe 2026

 

 

TO SPONSOR


Christian Larsmon

Christian.Larsmon@terrapinn.com


Stan Dooley

Stan.Dooley@terrapinn.com

 

TO SPEAK


Isla Sutherland

Isla.Sutherland@terrapinn.com

 

MARKETING & PRESS


Jasper Cameron

Jasper.Cameron@terrapinn.com

 

Stay Up-to-Date

Join our mailing list to receive exclusive content and offers.

By submitting, you agree to receive email communications from Terrapinn, including upcoming promotions and discounted tickets and news.